Donepezil Micro Pellets MUPS
Donepezil, marketed under the trade name Aricept by its developer Eisai and partner Pfizer, is a centrally acting reversible acetylcholinesterase inhibitor.
Its main therapeutic use is in the palliative treatment of mild to moderate Alzheimer's disease. Common side effects include gastrointestinal upset.
It has an oral bioavailability of 100% and easily crosses the blood-brain barrier. Because it has a half-life of about 70 hours, it can be taken once a day.
Donepezil Micro Pellets - Multiple Unit Particle System (MUPS)
Donepezil Micro Granules - Multiple Unit Particle System (MUPS)